A future based on a great foundation

FDA 510k-clearance for new disposable sensor intended for monitoring of children

Acquisition of Respiratory Motion

Strategic license and connectivity agreement with Masimo

CE-MDR approval for new disposable sensor intended for small children

Inauguration of Senzime’s manufacturing facility in Uppsala, Sweden.

Senzimes TetraGraph system and new manufacturing facility certified against MDR.

Listed on Nasdaq Stockholm’s main market.

Establishing a subsidiary in Germany, receives first breakthrough order from German university hospital.

Establishing a subsidiary in the US, Senzime Inc., builds a sales organisation and receives a breakthrough order from a US university hospital.

Marketing approval in the US, Japan and South Korea, allowing it to market and sell its products in these markets.

Senzime listed on Nasdaq Stockholm First North Growth Market.

Licensing agreement with Fukuda Denshi in Japan.

Senzime acquires Acacia Designs B.V. thereby obtaining TetraGraph^®, broadening the product range to include solutions for patients undergoing anaesthesia.

Senzime acquires MD Biomedical AB, the developer of OnZurf^®Probe, a new generation of microdialysis catheters.

Patent obtained for CliniSenz^®.

Senzime is admitted to trading on Aktietorget.

The first prototype is completed: CliniSenz – a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.

The Crafoord family, represented by Adam Dahlberg, invests in the company.

Senzime is founded with the business idea of developing patient-oriented systems for measuring life-critical substances.